Peer-reviewed veterinary case report
Testing glypican-3 and alpha-fetoprotein genes to detect liver cancer
By Phosri, Aphinan et al.·Published in Veterinary Integrative Sciences·2024·View original on Crossref →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: The Evaluation of Glypican-3 mRNA and Alpha-fetoprotein mRNA as biomarker for hepatocellular carcinoma in Dogs: A preliminary study
- Species:
- dog
Plain-English summary
A group of dogs was tested for liver cancer (hepatocellular carcinoma or HCC) by checking their blood and liver samples for specific gene markers called GPC-3 and AFP. The study found that while GPC-3 levels did not differ significantly between dogs with HCC and those with other liver diseases, there was a strong link between GPC-3 levels and liver enzyme levels in dogs with HCC. This suggests that GPC-3 could be a useful marker for diagnosing liver cancer in dogs, potentially leading to better diagnostic methods in the future.
People also search for: dog liver cancer symptoms · GPC-3 test for dogs · liver disease in dogs treatment
Abstract
Glypican-3 (GPC-3) and alpha-fetoprotein (AFP) are considered powerful biomarkers for human hepatocellular carcinoma (HCC). The elevation of GPC-3 and AFP gene expression is commonly found in individual HCC patients. The detection of these biomarkers can be achieved with the examination of blood or tissue samples. Moreover, mRNA expressing GPC-3 and AFP are evaluated for detecting HCC in patients. In veterinary practice, data on GPC-3 and AFP of gene expression remain limited. Therefore, this study aims to evaluate the GPC-3 and AFP gene expression in dogs with HCC compared with other hepatic diseases. Twenty dogs were divided into two groups: HCC (n=6), and non-HCC (n=6). The liver tissue and plasma samples of each group were examined for GPC-3 and AFP gene expression by qPCR. The results showed a no statistical difference in the expression levels of GPC-3 gene in liver and plasma samples of dogs with HCC compared with non-HCC dogs. However, there was a positive correlation between the expression of GPC-3 gene and levels of aspartate transaminase (AST) in the HCC group (p-value = 0.002, R = 0.967). Moreover, the sensitivity, specificity, and accuracy of GPC-3 gene expression were higher than AFP gene expression in the HCC group. Therefore, this study conveys the expression of GPC-3 gene and AFP gene, suggesting a potential association with the development of HCC in dogs. The findings, particularly regarding the GPC-3 gene, could contribute to improved diagnostic methods in the future.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on Crossref: https://doi.org/10.12982/vis.2025.076